Publications
Detailed Information
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility
Cited 7 time in
Web of Science
Cited 8 time in Scopus
- Authors
- Issue Date
- 2006-08-25
- Publisher
- Wiley-Blackwell
- Citation
- J Gastroenterol Hepatol. 2006 Oct;21(10):1590-5.
- Keywords
- 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use ; Amoxicillin-Potassium Clavulanate Combination/*contraindications ; Anti-Bacterial Agents/*contraindications ; Anti-Ulcer Agents/therapeutic use ; Biopsy ; Bismuth/therapeutic use ; Drug Therapy, Combination ; Endoscopy, Gastrointestinal ; Female ; Helicobacter Infections/*drug therapy/microbiology/pathology ; Helicobacter pylori/drug effects/*isolation & purification ; Humans ; Male ; Metronidazole/therapeutic use ; Middle Aged ; Organometallic Compounds/therapeutic use ; Pyloric Antrum/*microbiology/pathology ; Stomach Ulcer/drug therapy/microbiology/pathology ; Tetracycline/*contraindications ; Treatment Failure
- Abstract
- BACKGROUND: The purpose of the present paper was to evaluate the efficacy and tolerability of amoxicillin-clavulanate and tetracycline-based quadruple therapy as an alternative second-line treatment for H. pylori infection. METHODS: The study subjects consisted of 54 patients infected with H. pylori, in whom initial triple therapy had failed. Subjects were randomized to receive the following 7-day therapies: (i) pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin-clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d. (PBAT); or (ii) pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. (PBMT). Eradication rates based on antibiotic susceptibility, drug compliance and side-effect rates were evaluated and compared. RESULTS: The H. pylori eradication rates were 16.0%/17.4% with PBAT and 65.5%/70.4% with PBMT by intention-to-treat (P<0.001) and per-protocol analyses (P<0.001), respectively. In patients who received PBAT, the eradication rates were only 16.7% (2/12) for both amoxicillin and tetracycline-susceptible H. pylori strains. Drug compliance and side-effect rates were similar in the two groups. CONCLUSIONS: Despite high individual in vitro antimicrobial activity, amoxicillin-clavulanate and tetracycline-based quadruple therapy showed low eradication rates, which strongly suggests that it should not be considered as a therapeutic option for H. pylori eradication.
- ISSN
- 0815-9319 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16928222
https://hdl.handle.net/10371/27525
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.